Physician profile
John Charalambopoulos
NPI 1073769659
$1,347.79
in general payments reported to CMS, 2019-2025
12 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.78 · 2020: $37.73 · 2021: $61.96 · 2022: $62.98 · 2023: $289 · 2024: $428 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,171.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $359.40 | 2022-2025 | |
| Gilead Sciences, INC. | $328.94 | 2022-2025 | |
| Exact Sciences Corporation | $132.99 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $93.41 | 2023-2024 | Freestyle Libre 3 |
| Dynavax Technologies Corporation | $83.76 | 2023-2025 | Heplisav-B |
| Shield Therapeutics INC | $82.86 | 2023-2025 | Accrufer |
| Astellas Pharma US INC | $69.99 | 2024 | Veozah |
| Abbvie INC. | $66.59 | 2020-2021 | |
| Viiv Healthcare Company | $60.59 | 2023-2024 | Apretude |
| Bayer Healthcare Pharmaceuticals INC. | $33.10 | 2020-2021 | |
| Lilly USA, LLC | $22.38 | 2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $13.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Charalambopoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.